Affinivax

Acquired

GSK completes acquisition of Affinivax, Inc. | GSK

Cambridge, United States · Founded 2014 · $348.5M raised

Employees
51–200
Founded
2014
Business Model
B2B
Total Funding
$348.5M
Last Round
$226.0M Series CJan 2021
Rounds
4
Acquisition Date
May 2022

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Affinivax was a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2014, pioneering the Multiple Antigen Presenting System (MAPS) platform technology for next-generation vaccines. Its lead asset, a 24-valent pneumococcal vaccine (AFX3772), received FDA Breakthrough Therapy designation and was in Phase II trials when GSK acquired the company for $2.1 billion upfront in August 2022.

Summary

Affinivax is a Biotech company based in Cambridge, United States, founded in 2014. It has raised $348.5M in total across 4 rounds, most recently a $226.0M Series C round in Jan 2021.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionMay 2022

Sign up to see all 5 events

Funding: Seed through Series C. Amounts, valuations, and investors where available.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Affinivax on Indexed.vc
<a href="https://indexed.vc/companies/affinivax"><img src="https://indexed.vc/api/badge/company/affinivax" alt="Affinivax on Indexed.vc" width="260" height="76" /></a>